Literature DB >> 7106165

Monoamine oxidase inhibition by tranylcypromine: assessment in human volunteers.

P R Bieck, K H Antonin.   

Abstract

The inhibition of monoamine oxidase (MAO) by tranylcypromine was studied in 6 healthy volunteers given increasing doses of 10, 15, 20 and 25 mg/day over a 4-week period. Measurements were made of urinary tryptamine excretion, blood pressure response to tyramine (TY) and norepinephrine (NE), and subjective self-rating. A significant increase in urinary tryptamine, indicating the onset of MAO inhibition, occurred in all 6 subjects once the cumulative dose of 40 mg TC had been administered. Thereafter, urinary tryptamine increased up to 7-fold, dose-dependently with large interindividual variation (78 +/- 27 to 549 +/- 252 microgram/g creatinine). Within 4 days after stopping the drug, control values were reached again. The assessment of TY potentiation by comparison of equieffective doses (S dose) became up to 10 times more sensitive when both the height and the duration of the increase in systolic blood pressure (S AUC) were taken into account. The increases in tyramine sensitivity found with the highest cumulative doses of TC (5.4 +/- 0.8 mg/kg; n =6) were S dose from 8-16 and S AUC from 28-162, respectively. The pharmacodynamic half-life (Pd 1/2) of TC approximated a mean first fast Pd 1/2 of 1.3 d and a slower phase of 14.2 d. During treatment with the highest TC dose, resting blood pressure was significantly elevated from 120 to 128 mm Hg, and the pressor sensitivity to NE (S NE) in 4 of the 6 subjects rose, the mean was 1.7 (n = 6). In 3 volunteers NE sensitivity was normalized within 4 days after stopping TC. There was a significant correlation between increasing vigilance with TC dose in 5 volunteers (r = 0.81, n = 15, p less than 0.01). It is concluded that combination of the results of several tests has provided reliable information about the onset, extent and duration of MAO inhibition in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106165     DOI: 10.1007/BF00548397

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Identification and assay of urinary tryptamine: application as an index of monoamine oxidase inhibition in man.

Authors:  A SJOERDSMA; J A OATES; P ZALTZMAN; S UDENFRIEND
Journal:  J Pharmacol Exp Ther       Date:  1959-07       Impact factor: 4.030

2.  Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo.

Authors:  D S Robinson; W Lovenberg; H Keiser; A Sjoerdsma
Journal:  Biochem Pharmacol       Date:  1968-01       Impact factor: 5.858

Review 3.  Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids.

Authors:  E M DeMet; A E Halaris
Journal:  Biochem Pharmacol       Date:  1979-10-15       Impact factor: 5.858

4.  [Origin of homovanillic acid in the urine].

Authors:  J Raese; P Schmiedek; E Ehrlich
Journal:  Arzneimittelforschung       Date:  1974-08

5.  Inhibition of monoamine oxidase in man by furazolidone.

Authors:  W A Pettinger; F G Soyangco; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1968 Jul-Aug       Impact factor: 6.875

6.  Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.

Authors:  J H Cavanaugh; J D Griffith; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

Review 7.  Biochemical assessment of antidepressive drugs.

Authors:  K Ghose
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

8.  Assessment of Peripheral adrenergic activity and its interactions with drugs in man.

Authors:  K Ghose
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

9.  Effects of tranylcypromine stereoisomers on monamine oxidation in man.

Authors:  G P Reynolds; W D Rausch; P Riederer
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

10.  [Determination and comparison of the plasma and urine concentrations in men given tranylcypromine stereoisomers].

Authors:  A Lang; H E Geissler; E Mutschler
Journal:  Arzneimittelforschung       Date:  1979
View more
  5 in total

1.  Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029).

Authors:  Andrea F D Di Stefano; Milko Massimiliano Radicioni; Antonio Rusca
Journal:  Neurotox Res       Date:  2012-08-08       Impact factor: 3.911

2.  Intravenous amine pressor tests in healthy volunteers. Within- and between subject variances and sex differences.

Authors:  I W Reimann; L Firkusny; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

4.  Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A.

Authors:  P C Waldmeier; K H Antonin; J J Feldtrauer; C Grunenwald; E Paul; J Lauber; P Bieck
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Tyramine pressor sensitivity changes during deprenyl treatment.

Authors:  T Sunderland; E A Mueller; R M Cohen; D C Jimerson; D Pickar; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.